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Vandenberg et al. (2012) claim that ‘‘most if not all [endocrine-disrupting chemicals (EDCs)] are likely to
have low-dose effects’’ and ‘‘nonmonotonicity is a common occurrence after exposures to hormones and
EDCs in cell culture and animals and across human populations.’’ They present examples as anecdotes
without attempting to review all available pertinent data, selectively citing studies without evaluating
most of them or examining whether their putative examples are consistent and coherent with other rel-
evant information. They assume that any statistically signiﬁcant association indicates causation of an
adverse effect, and their limited evaluation of speciﬁc studies is not done uniformly (i.e., studies with
positive results are evaluated differently than those with null results). They also do not evaluate whether
exposures in studies are truly ‘‘low-dose’’ and relevant to humans. They propose a number of different
nonmonotonic dose–response curves, but do not consider reasons for why they should be expected to
apply generally across species. Many of their examples would be – and indeed have been – questioned
by many scientists. Overall, Vandenberg et al. put forth many asserted illustrations of their two conclu-
sions without providing sufﬁcient evidence to make the case for either and while overlooking evidence
that suggests the contrary.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
In their recent publication, Vandenberg et al. (2012) undertook
the formidable task of assessing whether endocrine-disrupting
chemicals (EDCs) as a whole challenge the traditional toxicology
concept that ‘‘the dose makes the poison.’’ Based on their assembly
of a number of examples, they conclude that ‘‘most if not all EDCs
are likely to have low-dose effects’’ and that ‘‘nonmonotonicity is a
common occurrence after exposures to hormones and EDCs in cell
culture and animals and across human populations.’’ According to
the authors, biological effects of concern are to be expected even
well below exposure levels traditionally deﬁned as no observed ad-
verse effect levels (NOAELs) with respect to the frank toxicity ob-
served at still higher exposures. They assert that, by failing to
explore dose levels below those found to avoid high-dose toxicity,
conventional toxicity testing of chemicals misleads us to believe
that still lower doses should be regarded as without adverse
consequences.
Our comments below are a direct response to this particular
review, but it should be noted that they also pertain more broadly
to several earlier publications that have argued for the theory ofversity Road, Cambridge, MA
. Rhomberg).
-NC-ND license.low-dose nonmonotonicity of endocrine-mediated effects (e.g.,
vom Saal et al., 2007). These earlier arguments have drawn their
own responses (e.g., Sharpe, 2010; Goodman et al., 2009).
If the conclusions of Vandenberg et al. were to be accepted as a
general proposition, there would be profound consequences for
toxicity testing and its interpretation in risk analysis and safety
assessment. It is therefore important to evaluate the basis for these
claims. Vandenberg et al. base their argument largely on assem-
bling a large set of putative examples of observed low-dose im-
pacts and nonmonotonic dose–response curves (NMDRCs) in
endocrine-mediated endpoints. In our view, the validity and inter-
pretation of many of these examples would be – and indeed has
been – questioned by many scientists familiar with the data and
details of each case. In the present brief critique, we cannot discuss
each of these examples, but it will be important to subject the
interpretations of Vandenberg et al. to wider scientiﬁc analysis be-
fore the commonness of such effects at low doses is accepted. Be-
low, we focus our comments on the methods for assembling and
interpreting the examples, as well as on the bearing of some gen-
eralized mechanisms that Vandenberg et al. put forth in support
of their hypothesis that nonmonotonicity is not only plausible,
but to be expected for endocrine-mediated effects.
At the outset, it is important to be clear that Vandenberg et al.
are not simply making the ‘‘no-threshold’’ argument (that frankly
adverse effects seen with high frequency at high doses also appear
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ments of practical sample sizes cannot detect the low rates of
occurrence). It also seems that they are not simply arguing that
high-dose testing discovers only ‘‘major’’ and obvious toxicities
while missing subtler adverse effects that might have lower
thresholds. For chemicals interacting with endocrine-mediated
processes, they argue that it should be common for perturbations
(of sufﬁcient magnitude to prompt health concern) to occur at sub-
stantial frequencies through a range of low exposure levels, even
when these same effects have not been observed at higher dose
levels.1
Although the authors discuss a large list of EDCs and endpoints
as examples of observed causal effects at low doses, they do not
actually evaluate the case for causality of any particular EDC and
endpoint with rigor. They present their examples essentially as
anecdotes without an attempt to review all of the available perti-
nent data, selectively citing studies without evaluating most of
them or examining whether the putative examples are consistent
and coherent with other relevant information. They assume that
any statistically signiﬁcant association is indicative of causation,
and their limited evaluation of speciﬁc studies is not done uni-
formly across studies. As noted above, many of their chosen exam-
ples would be – and indeed have been – questioned by many in the
scientiﬁc community. Vandenberg et al. put forth many asserted
illustrations of their two main conclusions (that ‘‘most if not all
EDCs are likely to have low-dose effects’’ and that ‘‘nonmonotonic-
ity is a common occurrence after exposures to hormones and EDCs
in cell culture and animals and across human populations.’’) with-
out providing sufﬁcient evidence to make the case for either and
while overlooking evidence that suggests the contrary.2. Weight of evidence
As discussed by Vandenberg et al., there are many ways to eval-
uate the weight of evidence (WoE). Several key aspects are central,
including a systematic review of relevant individual studies that ac-
counts for data quality and study reliability; a systematic evalua-
tion of consistency, speciﬁcity, and reproducibility of speciﬁc
outcomes; an articulation and evaluation of hypotheses that bear
on available data; and a comparison of how well each hypothesis
describes the available data (e.g., Kamrin, 2007; Rhomberg et al.,
2010; US EPA, 2011). While Vandenberg et al. list several purported
examples of low-dose effects, the majority consist of one study per
endpoint. There is no evaluation of the study noted or whether the
ﬁndings are consistent and coherent with other scientiﬁc evidence.
This is also true for their case studies. For example, for bisphenol A
(BPA)/prostate effects, Vandenberg et al. name one reasonwhy each
study with a null result should be ignored, give no reasons why
those with positive results should be considered indicative of cau-
sation, and do not evaluate whether positive results are consistent
with one another and BPA’s purported mode of action.
Kamrin (2007) suggested that reproducibility, consistency, and
proper conduct of studies are required to support the low-dose
hypothesis. Vandenberg et al., citing Kamrin, state they and others
agree with these criteria, with caveats. In practice, however, they
do not evaluate reproducibility or consistency with any speciﬁcity
(by comparing dose–response patterns or dose ranges over which
nonmonotonic effects are asserted across studies). They argue that
a single negative result (or even several studies showing negative1 We speak of ‘‘perturbation’’ instead of toxicity because Vandenberg et al
explicitly decline to distinguish between adverse and non-adverse effects; rather
they implicitly presume that all perturbations, being impositions on normal contro
processes, should be avoided. This approach fails to consider how dose–response
patterns for apical effects might differ from those for precursor perturbations and
components of the overall mode of action..
,
lresults) cannot negate other studies that show adverse effects be-
cause ‘‘it is more difﬁcult to actually ﬁnd effects, particularly when
using highly sophisticated techniques.’’ In a WoE analysis, one
evaluates all evidence – regardless of whether it is positive or neg-
ative – using the same criteria and determines whether it indicates
causation. One also evaluates the alternative hypothesis that
apparent positive results are statistical ﬂuctuations or the result
of confounding factors. Vandenberg et al. have not done this for
any EDC; further, by excluding negative data for not following
some uncommonly used experimental design but retaining posi-
tive ﬁndings for any experimental design, they create an inherent
bias toward positive studies. Using this logic, most potentially con-
tradictory results are excluded from consideration, yet positive
ﬁndings in almost all studies occur among null results for many
endpoints. How can null results be unquestionably ascribable to
study design issues but positive ones are unaffected?
Vandenberg et al. place great emphasis on their standards for
the proper conduct of studies, but they focus mainly on the use
of positive and negative controls and sensitive animal strains. In
practice, these criteria are used by Vandenberg et al. largely to dis-
miss studies containing negative ﬁndings that contradict the puta-
tive examples of low-dose effects. There is no discussion of other
aspects of study conduct, such as how endpoints are measured or
the statistical analyses used, that might affect results and their
interpretation. When evaluating consistency among studies, Van-
denberg et al. argue that every study may not show the same effect
if some studies use insensitive species. Although this is true,
ascribing a lack of effects to an inherent lack of sensitivity is itself
a scientiﬁc conclusion that should be subject to a WoE evaluation
that considers, among other factors, the historical record of the use
of the experimental system to show causation of the effects in
question. It is also important to consider whether available histor-
ical control data indicate that a strain or species is so prone to
developing a particular effect that its response to certain chemicals
overestimates human risks. That is, if effects of an agent are so ten-
uous as to appear only in particularly sensitive strains, it is not
clear that such effects should be deemed relevant for humans
(i.e., the reasoning for why humans should also be regarded as
especially sensitive needs to be evaluated). Similarly, automati-
cally ascribing an observed lack of effects in studies without posi-
tive controls to the lack of ability to show such effects (an
argument that is frequently raised by low-dose proponents, e.g.,
see vom Saal and Welshons, 2006) is presumptuous unless
couched in a WoE evaluation that considers the historical record
of the assay to show effects.
Other experimental design issues that would seem equally crit-
ical are not considered. For instance, Vandenberg et al. include a
section on the impact of intrauterine position – the placement of
individual fetuses in the uterine horns between neighbors of differ-
ent sexes – on subtle changes in endocrine-modulated effects.
Their point is to show that even such small changes in the hor-
monal environment as wrought by the sex of one’s uterine neigh-
bors can produce changes of the kind and magnitude that they also
ascribe to chemical exposures. But if this is so, then any chemical
study that does not control for intrauterine position is likely to
be susceptible to false positives arising from chance differences
among dose groups in the distribution of intrauterine positions.
Controlling for intrauterine position is rarely done, yet the impact
of this on potential false positive results is not considered in the
Vandenberg et al. analysis.3. Exposure
To assess whether effects occur at low doses, one must know
what a low dose is. Vandenberg et al. discuss many ways to deﬁne
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to which humans are exposed. To determine whether an EDC has a
low-dose effect, it is critical that it is studied at doses relevant to
assessing human risk. For the vast majority of EDCs listed by Van-
denberg et al., the relationship between exposures in the experi-
mental studies is not related to human exposures. In other cases,
estimates of human exposure are not based on a balanced review
of the literature.
For example, Vandenberg et al. claim that human exposure to
BPA is 400 lg/kg day based on one citation that did not adhere to
the basic principles of pharmacokinetics. Based on all of the avail-
able pharmacokinetic data, the US Food and Drug Administration
(FDA) recently reported mean dietary intake of BPA from its pres-
ence in food-contact articles to be 0.1–0.2 lg/kg day for children
and adults and 0.2–0.4 lg/kg day for infants (US FDA, 2009).
Vandenberg et al. acknowledge that exposure route can affect
the dose that reaches the target site, but they argue that the route
of exposure is not an issue as long as the dose that reaches the tar-
get site is applicable to humans. But EDCs given by alternative
routes of exposure can lead to concentrations at target sites that
are much higher than human exposures; in those instances, inves-
tigators are no longer assessing low-dose, but high-dose, effects. As
argued at length by Vandenberg et al., one cannot establish
whether low-dose effects are likely or even plausible if one only as-
sesses effects at high doses. To date, none of the non-oral rodent
studies of BPA have approached human exposures, and, while
these can be informative for assessing the overall WoE, they are
not informative regarding low-dose exposures.4. Biological effects
Vandenberg et al. state ‘‘any biological effect, whether it is ob-
served to follow linear relationships with administered dose or
not, provides conclusive evidence that an EDC has biological activ-
ity.’’ This simply presumes that the apparent effects are indeed
causal; as we have argued, such a conclusion is not self-evident.
It requires evaluation of study-by-study consistency and weighing
of contradictory data before being acceptable. Moreover, as dis-
cussed by Goodman et al. (2010), adaptive effects are non-adverse
biological effects, or perturbations, that reﬂect homeostasis, or the
body’s response to environmental stressors to maintain normal
biological function. Mere perturbations, such as compensatory ef-
fects that occur over a short period of time, transient effects that
are not sustained during exposure, reversible effects that cease
once exposure stops, and early precursor effects that are distant
from the apical effect, may not be adverse. Also, effects that are
sustained during exposure but are of low severity and do not lead
to any biological functional impairment may not be adverse. Van-
denberg et al. have made no efforts to distinguish these types of ef-
fects, calling any effect indicative of activity, insinuating adversity.
While it is true that a non-adverse effect could be a biomarker for
an apical effect, in any toxicity study, this must be evaluated. In
particular, biological effects that have a homeostatic response
should not be considered conclusive evidence of an EDC’s activity.
This holds for in utero exposures as well. Vandenberg et al. argue
that the fetus does not have fully developed systems for maintain-
ing homeostasis and will necessarily be particularly sensitive to
EDCs, yet there are many instances where this has been shown
not to be the case (e.g., BPA administered orally to rats is not found
in the fetus, and BPA in the fetus can be metabolized to its inactive
form; Doerge et al., 2011). As toxicology becomes more mechanis-
tic, all toxicity endpoints – not just those associated with endo-
crine perturbation – encounter this issue of how to use
observations of early events at lower levels of organization as indi-
cators of potential apical toxicity. To simply decline to distinguishperturbation and modulation from dysfunction dodges this key
question and is retrogressive, stepping away from the insights con-
tributed to modern toxicology by considering mode of action.
In addition, the fact that a biological effect is observed, be it ad-
verse or not, does not mean it was caused by an EDC. An exposure
is not likely to be causal if a biological effect is not statistically sig-
niﬁcantly different in exposed and non-exposed study subjects;
isolated (occurring in very few study subjects) or independent
(occurring in the absence of other effects that are expected via
the same mode of action); secondary to primary exposure-related
effects; observed because of study limitations; or unrelated to the
apical effect and not associated with functional impairment (Good-
man et al., 2010). Vandenberg et al. assert effects from dozens of
EDCs without an evaluation of any of these factors, which often im-
pact the interpretation of results.5. Nonmonotonic dose–response
Vandenberg et al. state that NMDRCs occur in cell culture,
animal, and epidemiology literature and ‘‘it is plausible
that. . .NMDRCs are not the exception but should be expected and
perhaps even common.’’ Vandenberg et al. have shown that this
phenomenon is in the realm of possibility, but have not shown that
nonmonotonicity is actually demonstrated in any particular case. If
enough parameters are used to model a dose–response function, it
will always be possible to ﬁt curves to the variable response pat-
terns observed for some biological endpoints. It is critical, however,
to distinguish between reﬂecting a true biological response and
simply over-ﬁtting patterns of study-speciﬁc dose-by-dose ﬂuctu-
ations that occur by chance alone. In the case of traditional mono-
tonic dose–response relationships, it is the very constraint of
assumedmonotonicity that provides the statistical basis for sorting
out trends from random statistical ﬂuctuations. If this presumption
is abandoned, it places especial importance on being able to repeat
the ﬁndings, with similar nonmonotonic patterns of dose-depen-
dence, if one is to claim the patterns as real phenomena and not
just study-speciﬁc patterns of error. Without a priori expectations
of dose–response curve shape, this is the only basis for establishing
generalizable dose–response phenomena empirically. Vandenberg
et al. have not shown that statistically signiﬁcant results (or even
trends that are not statistically signiﬁcant) are observed with any
consistent patterns across studies for any particular EDC and end-
point. Although they have put forth possible mechanisms that
could generate nonmonotonicity, they have not shown that these
mechanisms actually operate for particular EDCs. For instance,
studies using estrogen and androgen antagonists can help to dem-
onstrate the role of particular mechanisms and putative outcomes,
but these studies have not been brought to bear to establish how
speciﬁc interactions with the endocrine system bring about certain
dose–response phenomena.
A contrasting perspective has recently been articulated in a
commentary by Wolff (2011) on epidemiology studies of BPA, for
which, like many other EDCs, most exposures are low and ranges
small. This leads to low statistical power and, sometimes, specimen
contamination can account for some measured biomarker levels.
Wolff notes that this can lead to a high noise-to-signal ratio, caus-
ing ‘‘unusual statistical associations, including inverse relation-
ships.’’ Some studies use a one-time measurement that may be
poorly correlated with exposure at some earlier critical time at
which the putative causal processes would operate. For these rea-
sons, single instances of a positive association in a study, even if
statistically signiﬁcant, should not be taken as sufﬁcient evidence
of causation, as Vandenberg et al. have done uncritically in their
evaluation of not only human studies, but experimental studies
as well (e.g., Elswick et al., 2000, 2001).
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the doses at which they purport effects occur vary across EDCs.
They do not evaluate whether these dose levels are applicable to
human exposures, nor do they consider reasons for why the pat-
terns should be expected to apply generally across species.
6. Mechanisms for nonmonotonicity
Vandenberg et al. review a number of potential mechanisms
by which complex biological interactions could generate non-
monotonic relationships. It is noteworthy that the examples they
show are all of phenomena that happen at substantial dose lev-
els, much higher than typical human exposures. Moreover, they
are largely examples of effects on quantitative continuous end-
points (for which the magnitude of a physiological effect is the
outcome), rather than changes in the incidence of all-or-none
effects. Such relationships between dose and the changing
magnitude of continuous endpoints are sometimes termed
dose–effect curves (to distinguish them from dose–response
curves that trace the probability of a quantal response as a func-
tion of dose). Tying changes in continuous variables to changes
in incidence rates of distinct disease states is a challenge for
mechanistic toxicology, but the issue is elided in the Vandenberg
et al. treatment.
The various mechanisms have in common that the changes in
direction of the measured endpoint with increasing dose arise be-
cause some countervailing effect (which also increases with dose)
acts to extinguish or quash it (by killing the target cells, down-reg-
ulating the receptor, or saturating a competing process, etc.). These
countervailing mechanisms themselves are major effects that
would require substantial exposures; moreover, they should cause
other observable consequences and physiological disruptions. That
is, even though these mechanisms may prevent one key endpoint
at a high dose, they should still affect physiology in some observa-
ble way. Indeed, they might well be recognized as toxicity in their
own right. It is not clear how such mechanisms would be able to
operate in a way that produces apparently unaffected individuals
at an intermediate dose and yet prompt dysfunction at lower
doses.
7. Conclusions
The Vandenberg et al. analysis framework lacks the scientiﬁc
rigor necessary for an objective evaluation of the extent to which
a body of scientiﬁc evidence does, or does not, support the NMDR
hypothesis. In our view, the case for widespread nonmonotonicity
leading to undetected toxicity at low doses has not been made, and
indeed cannot be made, simply through assembling selected cases
that are presumed to represent causal effects while ignoring
contradictory ﬁndings.Conﬂict of interest statement
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